DelveInsight’s “Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2032″ report provides a comprehensive insight into the historical and projected epidemiology, along with market trends for Psychosis in Parkinson’s Disease and Alzheimer’s Disease in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To Know in detail about the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Forecast
Some of the key facts of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report:
- The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market size was valued approximately USD 1,229 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Acadia’s NUPLAZID (pimavanserin) stands as the sole approved product for PDP (Parkinson’s Disease Psychosis) in the US. While it is still under investigation for ADP (Alzheimer’s Disease Psychosis), it carries a boxed warning concerning heightened mortality risks observed in elderly patients with psychosis related to dementia.
- Several medications are in various stages of development to address psychosis in Parkinson’s Disease and Alzheimer’s Disease, yet only a limited number are in advanced stages. Examples include Karuna Therapeutics’ KarXT (xanomeline-trospium), Sunovion Pharmaceuticals’ Ulotaront (SEP-363856), and Vanda Pharmaceuticals’ FANAPT (iloperidone). These are expected to be introduced to the market within the forecast period spanning from 2023 to 2032.
- In 2022, the combined diagnosed prevalent cases of Psychosis in PD (Parkinson’s Disease) and AD (Alzheimer’s Disease) across the 7MM reached around 6,737,337 cases. Projections indicate an anticipated increase by 2032 at a Compound Annual Growth Rate (CAGR) of 2.4% throughout the study period from 2019 to 2032.
- In 2022, the United States represented approximately 34% of the diagnosed prevalent cases of Psychosis in PD (Parkinson’s Disease) and AD (Alzheimer’s Disease) within the 7MM. This proportion is anticipated to rise further by the year 2032.
- In the United States, there were an estimated 675,948 cases in males and 503,305 cases in females affected by PD (Parkinson’s Disease) in 2022. These figures are projected to rise by the year 2032
- In the year 2022, the number of AD (Alzheimer’s Disease) cases among males in EU4 and the UK was approximately 1,454,541, while among females, it reached nearly 3,487,835 cases. These figures are anticipated to increase by the year 2032.
- In 2022, Germany contributed to roughly 18% of the total diagnosed prevalent cases of PD (Parkinson’s Disease) within the 7MM. These cases are projected to rise at a Compound Annual Growth Rate (CAGR) of 1.7% during the study period from 2019 to 2032.
- Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapeutics, Merck Sharp & Dohme, and others
- Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
- The Parkinson’s Disease epidemiology based on gender analyzed that in the US, males diagnosed with PD are higher in number than females
- The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psychosis in Parkinson’s Disease and Alzheimer’s Disease pipeline products will significantly revolutionize the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market dynamics.
Psychosis in Parkinson’s Disease and Alzheimer’s Disease Overview
The National Institute of Mental Health (NIMH) defines psychosis as a group of symptoms affecting the mind in which there has been a partial loss of reality awareness. People have disruptions in their thoughts and perceptions during a psychotic episode, making it difficult for them to distinguish between reality and illusion.
In Parkinson’s disease (PD) and Alzheimer’s disease (AD), psychosis develops as a result of both endogenous (associated with the disease process) and exogenous (drugs, for example).
Get a Free sample for the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market
Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology Segmentation:
The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
- Prevalent Cases of Psychosis in Parkinson’s Disease and Alzheimer’s Disease by severity
- Gender-specific Prevalence of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
- Diagnosed Cases of Episodic and Chronic Psychosis in Parkinson’s Disease and Alzheimer’s Disease
Download the report to understand which factors are driving Psychosis in Parkinson’s Disease and Alzheimer’s Disease epidemiology trends @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology Forecast
Psychosis in Parkinson’s Disease and Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market or expected to get launched during the study period. The analysis covers Psychosis in Parkinson’s Disease and Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies and Key Companies
- KarXT: Karuna Therapeutics
- Ulotaront: Sunovion Pharmaceuticals
- FANAPT: Vanda PharmaceuticalsF
- ITI-1284: Intra-Cellular Therapeutics
- MK-8189: Merck Sharp & Dohme
Discover more about therapies set to grab major Psychosis in Parkinson’s Disease and Alzheimer’s Disease market share @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Treatment Landscape
Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Strengths
- Increased awareness and a more in-depth understanding of the disease pathophysiology has improved diagnosis and treatment.
- The recent US FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with PD Psychosis, indicates a positive change in treatment paradigm.
Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Opportunities
- There are opportunities for pharma players to develop therapies with improved safety and tolerability profiles, effectively reducing symptoms and preventing the recurrence of Psychosis in PD and AD.
- Advancement in biomarkers for cognitive decline allows precise diagnosis and individualized treatments
Scope of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapeutics, Merck Sharp & Dohme, and others
- Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
- Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapeutic Assessment: Psychosis in Parkinson’s Disease and Alzheimer’s Disease current marketed and Psychosis in Parkinson’s Disease and Alzheimer’s Disease emerging therapies
- Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Dynamics: Psychosis in Parkinson’s Disease and Alzheimer’s Disease market drivers and Psychosis in Parkinson’s Disease and Alzheimer’s Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Psychosis in Parkinson’s Disease and Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Access and Reimbursement
To know more about Psychosis in Parkinson’s Disease and Alzheimer’s Disease companies working in the treatment market, visit @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report Introduction
2. Executive Summary for Psychosis in Parkinson’s Disease and Alzheimer’s Disease
3. SWOT analysis of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
4. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Patient Share (%) Overview at a Glance
5. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Overview at a Glance
6. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Disease Background and Overview
7. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
9. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Current Treatment and Medical Practices
10. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Unmet Needs
11. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Emerging Therapies
12. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Outlook
13. Country-Wise Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Analysis (2019–2032)
14. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Access and Reimbursement of Therapies
15. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Drivers
16. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Barriers
17. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Appendix
18. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/